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Our previous finding of RTVP1 (GLIPR1) as a p53 target gene with tumor suppressor functions prompted us to initiate a genome-wide
sequence homology search for RTVP1/GLIPR1-like (GLIPR1L) genes. In this study we report the identification and characterization of a novel
p53 target gene cluster that includes human RTVP1 (hRTVP-1) together with two GLIPR1L genes (GLIPR1L1 and GLIPR1L2) on human
chromosome 12q21 and mouse Rtvp1 (mRTVP-1 or Glipr1) together with three Glipr1-like (Glipr1l) genes on mouse chromosome 10D1.
GLIPR1L1 has two and GLIPR1L2 has five differentially spliced isoforms. Protein homology search revealed that hRTVP-1 gene cluster members
share a high degree of identity and homology. GLIPR1L1 is testis-specific, whereas GLIPR1L2 is expressed in different types of tissues, including
prostate and bladder. Like hRTVP-1, GLIPR1L1 and GLIPR1L2 are p53 target genes. The similarities of these novel p53 target gene cluster
members in protein structure and their association with p53 suggest that these genes may have similar biological functions.
© 2006 Elsevier Inc. All rights reserved.Keywords: GLIPR1; RTVP1; GLIPR1L1; GLIPR1L2; p53 target genes; RTVP1/GLIPR1 gene cluster; Prostate cancer; Bladder cancerThe tumor suppressor gene p53 is the most commonly
mutated gene in human cancer. The protein that it encodes is a key
regulator of cell cycle, DNA repair, senescence, cell differenti-
ation, and apoptosis [1–5]. Mutations in the p53 gene can lead to
critical cellular malfunctions that contribute to malignant growth
and metastasis [6–9]. In prostate cancer, p53mutations are found
in relatively low frequencies in early, localized tumors, but occur
in significantly higher frequencies in advanced, hormone-
refractory metastatic tumors [7,8,10,11]. The established associ-
ation between loss of p53 function and prostate cancer metastasis
prompted us to pursue the identification, characterization, and
functional analysis of p53 target gene in prostate cancer.
Human RTVP1/GLIPR1 (hRTVP-1, HGNC approved gene
symbol: GLIPR1) was initially identified in human glioblastoma
and was referred asGLIPR1 (glioma pathogenesis-related protein
1) [12] or RTVP1 (related to testes-specific, vespid, and
pathogenesis protein 1) [13]. It was also identified as a marker⁎ Corresponding author. Fax: +1 713 794 7983.
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0888-7543/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygeno.2006.03.021ofmyelomocytic differentiation inmacrophage [14]. TheRTVP-1
protein shares significant sequence homology with members of
the pathogenesis-related protein (PR) superfamily that is
characterized by a PR domain harboring six blocks of consensus
sequences [15,16] and the cysteine-rich secretory protein (CRISP)
family that is characterized by a PR domain together with a
distinct cysteine-rich domain at the carboxyl terminus [17,18].
PR/CRISP proteins are involved in a variety of physiological
processes, including innate immunity, male fertility, fertilization,
inhibition of calcium/potassium channels and proteases, and
interaction with immunoglobulin proteins [17–23].
Mouse Rtvp1/Glipr1 (mRTVP-1, approved gene symbol:
Glipr1) was one of the p53 target genes identified in our initial
screening using differential display PCR [24]. Functional
analysis demonstrated that mRTVP-1 and hRTVP-1 have
proapoptotic activities in prostate and bladder cancer cells
[24,25]. Analysis of hRTVP-1 expression showed that the gene
is down-regulated through gene methylation in prostate cancer
tissues [25]. Adenoviral vector-mediated gene delivery of
mRTVP-1 in an orthotopic, metastatic mouse model of prostate
164 C. Ren et al. / Genomics 88 (2006) 163–172cancer significantly reduced primary tumor wet weight and
spontaneous metastasis to lung [26].
The identification of RTVP1 as a p53 target gene with tumor
suppressor functions encouraged us to initiate a genome-wide
sequence homology search for RTVP1/GLIPR1-like (GLIPR1L)
genes. In this study we report the identification and character-
ization of a novel p53 target gene cluster that includes hRTVP-1
together with two humanGLIPR1L (GLIPR1L1 andGLIPR1L2)
genes on human chromosome 12q21 and mRTVP-1 together
with three Glipr1l genes on mouse chromosome 10D1. Our
analysis of this novel p53 target gene cluster provides new and
important information for the future functional studies of this
gene cluster for their roles in the development, progression, and
potentially treatment of prostate cancer and other malignancies.
Results
Identification of GLIPR1L and Glipr1l genes
A genome-wide sequence homology search using hRTVP-1
and mRTVP-1 sequences led us to identify two human DNA
sequences (hypothetical proteins MGC26856 (GLIPR1L1) and
MGC39497 (GLIPR1L2) and three mouse DNA sequences
(1700011E04Rik (Glipr1l1), 4921508O11Rik (Glipr1l2), and
LOC544736 (Glipr1l3)) that share significant DNA sequence
homology with RTVP1. Interestingly, these GLIPR1L and
Glipr1l genes are located very near RTVP1 (within a 170 kb
range) and constitute gene clusters on human chromosome
12q21 and mouse chromosome 10D1, respectively (Figs. 1A
and 1B). Full-length GLIPR1L1 and GLIPR1L2 cDNAs were
cloned from human testis RNA using RT-PCR together withFig. 1. Chromosome localization of RTVP1 gene cluster. (A) Human RTVP1 gen
GLIPR1L1, and GLIPR1L2. (B) Mouse RTVP1 gene cluster on mouse chromosome
arrows indicate the direction of gene transcription.primers derived from sequences of hypothetical proteins
MGC26856 and MGC39497. Two transcripts were obtained
from GLIPR1L1 RT-PCR and subsequently identified as two
differentially spliced mRNAs from the same gene. These two
GLIPR1L1 isoforms were designated as GLIPR1L1α and
GLIPR1L1β. The only transcript obtained from GLIPR1L2
RT-PCR was designated as GLIPR1L2α. To isolate potential
isoforms of GLIPR1L1 and GLIPR1L2, cDNAs of GLIPR1Lα
and GLIPR1L2α were used as probes to screen a human testis
cDNA library. After three rounds of screening, 30 positive
clones were isolated for GLIPR1L1 and 37 positive clones were
isolated for GLIPR1L2. The 30 GLIPR1L1 clones were sorted
into two groups by PstI and SfiI restriction mapping and the 37
GLIPR1L2 clones were sorted into five groups by NdeI and SfiI
restriction mapping. Three clones from each group were
sequenced and the DNA sequences were mapped using
available genomic sequence. The results confirmed the two
isoforms of GLIPR1L1 (GLIPR1L1α and GLIPR1L1β) and
revealed four additional isoforms of GLIPR1L2 (GLIPR1L2β,
γ, δ, and ε). The structures and alternative transcripts of
GLIPR1L1 and GLIPR1L2 are summarized in Figs. 2A and 2B.
Sequence comparison of RTVP1 gene cluster proteins
A sequence homology comparison with known protein
sequences revealed that hRTVP-1 shares significant homology
with PR/CRISP proteins within the PR domain characterized by
an N-terminal signal peptide, an N-terminal sequence immedi-
ately following the signal peptides, six blocks of consensus
sequences (including two extracellular protein signature
motifs), and distinct C-terminal sequences (Fig. 3).e cluster on human chromosome 12q21, which includes hRTVP-1 (GLIPR1),
10D1, which includes mRTVP-1 (Glipr1), Glipr1l1, Glipril2, and Glipr1l3. The
Fig. 2. Alternative transcripts of GLIPR1L1 and GLIPR1L2. (A) GLIPR1L1 isoforms; (B) GLIPR1L2 isoforms. E stands for exon. Sig stands for extracellular protein
signature motif. Alt 5′ represents alternative splicing site.
165C. Ren et al. / Genomics 88 (2006) 163–172A comparison of deduced protein sequences among RTVP1
gene cluster members showed that member proteins share 35–
95% identity and 44–98% homology (Fig. 4 and Table 1). Most
members have a putative N-terminus signal peptide and all
members, except for GLIPR1L2ε, contain two extracellular
protein signature motifs (Figs. 4 and 5). These two characteristics
(signal peptide and extracellular protein signature motifs) suggest
that most of the gene cluster proteins are located on the surface of
the cell membrane or secreted. hRTVP-1; GLIPR1L2β, γ, δ;
mRTVP-1; and Glipr1l2 contain a transmembrane domain,
whereas GLIPR1L1α and β, GLIPR1L2α and ε, Glipr1l1, and
Glipr1l3 do not have this domain (Figs. 4 and 5), suggesting
different capacities for secretion. Our experience in recombinant
protein production has shown that GLIPR1L1α and GLIPR1L1βhave significantly higher secretory activities compared to
hRTVP-1 (data not shown). Interestingly, GLIPR1L2β, γ, and
δ andGlipr1l2 have an unusual glutamate-rich domain (ERD) that
contains 32 glutamate residues within a sequence of 53 amino
acid residues (Figs. 4 and 5). The function of the ERD is unclear.
In our data search, we also found a human sequence that is
located at chromosome 9p12–p13 and shares slightly lower
identity (32%) and homology (52%)with hRTVP-1. This gene was
identified and cloned in 2002 and was termed as C9orf19 [40] or
Golgi-associated PR-1 protein [27]. Although the crystal structure
of this protein was resolved recently [28], little functional
information is available at this point. We did not include this
gene in the present study since our focus was limited to the gene
clusters on human chromosome 12 and mouse chromosome 10.
Fig. 3. Homology comparison of hRTVP-1 with PR/CRISP proteins. Identity of amino acid residues is indicated with black-shaded columns, homology of amino acid
residues is indicated with gray-shaded columns, cysteines are indicated with orange-shaded columns. Six consensus blocks and extracellular protein signature motifs
within PR domain are indicated under the corresponding sequences. Signal peptides are indicated using orange letters and the transmembrane domains are shown using
pink letters.
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To determine expression levels for hRTVP-1 andGLIPR1Ls in
different human tissues,we analyzedmRNA levels of these genes
in human prostate, kidney, bladder, testis, lung, and bone marrow
using QRT-PCR. The results showed that hRTVP-1 is expressed
in all six tissues examined, with relatively higher mRNA levels in
prostate, testis, lung, and bonemarrow and relatively lower levels
in kidney and bladder (Fig. 6). In contrast to the widespread
expression of hRTVP-1, the expression of GLIPR1L1 is highly
tissue-specific, with very high mRNA levels in testis, a trace
amount in bladder, and undetectable expression in prostate,
kidney, lung, and bone marrow. Similar to GLIPR1L1,
GLIPR1L2 is highly expressed in testis; however, relatively
low level GLIPR1L2 expression was detected in the other five
tissues (Fig. 6). Our data demonstrating a unique hRTVP-1
expression pattern and tissue-specific expression of GLIPR1L1
are consistent with a recently published DNA microarray survey
of gene expression in normal human tissues [29].
RTVP1 gene cluster members are p53 target genes
Our initial studies demonstrated that mouse and human
RTVP1 are p53 direct target genes and are up-regulated by p53
expression and induction of DNA damage [24,25]. To extend
these observations toRTVP1 gene cluster members, we analyzed
the published genomic sequences/region (AC121761) of
hRTVP-1, GLIPR1L1, and GLIPR1L2 on human chromosome
12q21 in the National Center for Biotechnology Informationgenome database for potential p53-binding sites. For the hRTVP-
1 genomic sequence, in addition to the p53-binding site (p53-bs)
in the promoter region (site A) that was identified and
characterized in our initial studies [25], we identified two
additional p53-bs, site B in intron 2 and site C in intron 3. Both
sites contain a single base alteration in each half-site compared
with the p53 consensus binding site (cbs) (Fig. 7A and [30]).
Four potential p53 cbs were identified in intron 2 and intron 4 of
GLIPR1L1 sequences. Sites C1 and C2 share a common half-
site, that is, the second half-site of C1 serves as the first half-site
of C2 (Fig. 7A). Three potential p53-bs were identified in
GLIPR1L2 sequences, with site A in the promoter region, site B
in intron 2, and site C in intron 4 (Fig. 7A).
To test the functionality of these potential p53-bs, we
constructed luciferase reporters using these p53-bs in a
luciferase reporter vector containing a minimum SV40
promoter (pGL3-pro). Cotransfection with wild-type p53
strongly activated hRTVP-1 p53-bs-mediated luciferase activity
(∼12-fold for site A, ∼10-fold for site B, and ∼52-fold for site
C). Similarly, wild-type p53 also strongly activated GLIPR1L1
or GLIPR1L2 p53-bs-mediated luciferase activity, with ∼25-
fold for GLIPR1L1 site B, ∼12-fold for GLIPR1L2 site B.
Mutant p53 and empty vector failed to activate luciferase
activity mediated by these p53-bs (Fig. 7B). These data suggest
that like hRTVP-1, GLIPRIL1 and GLIPR1L2 are p53 target
genes and that GLIPR1L1 and GLIPR1L2 may have specific
biological functions that overlap with that of hRTVP-1.
To analyze the effects of p53 overexpression on endogenous
hRTVP-1, GLIPR1L1, or GLIPRI12 gene expression we used
Fig. 4. Protein homology comparison within RTVP1 gene cluster members. Domains/motifs are shown as described in the legend to Fig. 3. The glutamate (E)-rich
domain is indicated with green letters.
167C. Ren et al. / Genomics 88 (2006) 163–172two different systems to induce p53 expression and then
quantitated mRNA levels (QRT-PCR) for hRTVP-1, GLIPR1L1,
andGLIPR1L2. In 293 PE cells, adenoviral vector-mediated p53
gene delivery led to up-regulation of all three genes (3.3-fold for
hRTVP-1, 4.1-fold for GLIPR1L1, and 2.1-fold for GLIPR1L2)
compared to control virus Ad-lacZ (Fig. 8A). In the TSU-Pr1
p53 stable clone, induction of p53 expression by doxycycline
also stimulated the expression of hRTVP-1, GLIPR1L1, and
GLIPR1L2 in a similar pattern (Fig. 8B). These data confirm
hRTVP-1, GLIPR1L1, and GLIPR1L2 as p53 target genes.
Discussion
Loss of p53 function is the most frequently observed
phenomenon in human cancer [6–9,31]. There are multiplemechanisms that lead to loss of p53 functions. Normal p53
function can be lost when one allele of the gene or the
chromosome 17p13 region is deleted and a subtle mutation
occurs in the other allele [32]. In many cases a missense
mutation occurring in one allele is sufficient to inactivate p53
function [33]. Mutation or aberrant regulation of p53 target
genes can be another important mechanism. For example,
amplification of p53 target gene and negative regulator MDM2
can result in a similar loss of functional p53 through binding and
subsequent degradation of p53 [34–37]. p53-responsive cell
cycle regulator p21 and apoptosis regulator Bax are found
mutated or lost in multiple types of human cancer [38,39].
However, the relationship between mutation/loss of function for
p53 target genes and p53 mutation/loss of function per se within
the context of tumor progression has not been fully clarified.
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168 C. Ren et al. / Genomics 88 (2006) 163–172In light of the critical role of p53 in human cancer and its
association with prostate cancer metastasis, we identified novel
p53 target genes and analyzed the molecular mechanisms by
which these p53 target genes are regulated. In our initial studies
we identified mRTVP-1 and hRTVP-1 as p53 target genes and
reported that hRTVP-1 is inactivated by methylation in prostate
cancer [24,25]. We also demonstrated that RTVP1 had
proapoptotic activities in vitro and that adenoviral vector-
mediated delivery of mRTVP-1 led to suppression of primary
tumor growth and metastasis in a mouse prostate cancer model
[26]. In this study we identified GLIPR1L1, GLIPR1L2,
Glipr1l1, Glipr1l2, and Glipr1l3 as members of an RTVP1-
related gene cluster. We demonstrated that all three human genes
in this cluster are direct targets of p53. In our extended, broader
search for p53-bs in the hRTVP-1 molecule we identified two
p53-bs, site B and site C, in addition to site A, which was
identified in our initial studies (Fig. 7A). These two new sites
have comparable (site B) or increased (site C) efficiency
compared to site A inmediating wild-type p53-activated reporter
activities (Fig. 7B). We also identified four p53-bs inGLIPR1L1
with 4- to 25-fold inducibility and three p53-bs in GLIPR1L2
with 2- to 12-fold inducibility (Fig. 7). Up-regulation of
endogenous hRTVP-1, GLIPR1L1, or GLIPR1L2 gene expres-
sion by p53 was demonstrated through adenoviral vector-
mediated p53 gene delivery in 293 PE and through induction of
p53 expression in a TSU-Pr1 p53-stable clone. The results of
these studies showed that hRTVP-1, GLIPR1L1, and GLIPR1L2
are p53 target genes. The extent of up-regulation of hRTVP-1,
GLIPR1L1, or GLIPR1L2 expression by p53 is moderate (1- to
8-fold) compared to that in binding site reporter assays (12- to
52-fold), reflecting the complexity of gene regulation within the
cellular context. We also show that GLIPR1L1 and GLIPR1L2
are highly tissue-specific, with high expression levels in testis
but very low or undetectable expression levels in other tissues
(see Fig. 6), suggesting important regulators other than p53, such
as positive or negative tissue-specific cofactors are involved in
regulation of GLIPR1L genes. In addition to the pattern of
tissue-specific GLIPR1L gene expression described in this
paper, our previous studies [25] and our unpublished data
indicate that methylation in the regulatory regions of this group
of genes leads to down-regulation of these genes in prostate
cancer. Further studies are necessary to detail the complex
regulation of this unique gene cluster.
Another interesting point is that RTVP-1 cluster proteins
share significant sequence homology with PR/CRISP proteins.
They all contain a distinct PR domain that was initially identified
in plants as pathogenesis-related protein and is implicated in
innate immunity [20]. Most of them possess a putative signal
peptide, two extracellular protein signature motifs (Figs. 4 and
5), indicating that most of proteins in this category are
potentially secreted. Given the tissue-specific expression of
GLIPR1L1 and relatively low level of GLIPR1L2 expression in
tissues other than testis, it is important to know whether the
capacity of secreted GLIPR1L1 or GLIPR1L2 includes tumor
suppression functions in addition to testis-related physiological
functions. For example, local paracrine or potentially endocrine
functions for these proteins may expand their roles as growth
Fig. 5. Summary of domain/motif structures of RTVP-1 gene cluster proteins. PRD, pathogenesis-related protein domain; SP, signal peptide; sig, extracellular protein
signature motif; TMD, transmembrane domain; ERD, glutamate-rich domain. The number at the end of each protein indicates the number of amino acids.
169C. Ren et al. / Genomics 88 (2006) 163–172regulators for cancer control and potentially within other
biological contexts. Although RTVP1 gene cluster proteins
share many similarities, unlike RTVP1, GLIPR1L1α and β,
GLIPR1L2α and ε do not contain transmembrane domains
(Figs. 4 and 5), suggesting these proteins/isoforms may have a
higher capacity for secretion. Our initial studies demonstrated
that those isoforms with signal peptides but not transmembrane
domains, such as GLIPR1L1α, GLIPR1L1β, and GLIPR1L2α,
are predominately secreted, whereas those with both signal
peptides and transmembrane domains, such as hRTVP-1, are
only partially secreted (unpublished data). GLIPR1L2β and
GLIPR1L2γ, which lack signal peptides and contain transmem-
brane domains, are not expected to be secreted. Overall our data
suggest that a signal peptide is required for protein secretion, andFig. 6. The mRNA expression levels of hRTVP-1, GLIPR1L1, and GLIPR1L2 in six h
levels of 18S rRNA in the same samples. Bars stand for standard errors.the transmembrane domain functions as a negative factor for
protein secretion. A unique ERD was found in the C-terminus of
GLIPR1L2β, γ, and δ and Glipr1l2. Homology search using the
ERD sequence did not match to any known sequence in the
database. The function of ERD in these isoforms is unclear.
Further characterization of these distinct isoforms will be
completed in our future studies.
In summary, we identified a novel p53 target gene cluster on
human chromosome 12 and mouse chromosome 10. These gene
cluster proteins share significant identity and homology. The
results of our studies not only contribute this gene cluster to the
list of p53 targets, but also provide important information for the
future functional studies of this gene cluster. On the basis of the
similarities in protein structure and the association with p53uman tissues were determined by QRT-PCR and were normalized by expression
Fig. 7. Identification of p53 binding sites in hRTVP-1, GLIPR1L1, and GLIPR1L2. (A) Potential p53 binding sites in hRTVP-1, GLIPR1L1, and GLIPR1L2. (B)
Luciferase reporter assays. Luciferase activities were determined 24 h after transfection and were expressed as fold of control (control = luciferase reporter
vector + pCDNA empty vector). In the p53 cbs, R is purine, Y is pyrimidine, W is A or T, and n is 0 to 13 of any base. Bars stand for standard errors.
170 C. Ren et al. / Genomics 88 (2006) 163–172tumor suppressor, we speculate that this group of genes may
have similar biological functions and may have important roles
in the development, progression, and potentially treatment of
prostate cancer and other malignancies.
Materials and methods
Cloning and vector construction
Full-length cDNA of hRTVP-1 was cloned from human prostate RNA by
RT-PCR using the following primer pair: 5′-ACTCAGGCAATCACACTCTC-
3′ and 5′-GGTTGGTTTTTGGGTTTT-3′. GLIPR1L1α and GLIPR1L2α were
cloned from human testis RNA by RT-PCR using the following primer pairs: 5′-
CATCCTCCGCATCCTCCA-3′ and 5′-TAGGTATCAGGCAAGAGTGTA-3′for GLIPR1L1α; 5′-GGTGAACCATGGAGGCCG-3′ and 5′-GGGGAAG-
GAATAGGGTTAAGAT-3′ for GLIPR1L2α. The PCRs were performed using
Qiagen’s HotstarTaq PCR Kit (Qiagen, Valencia, CA, USA). The resulting PCR
products were constructed into the pGEM-T Easy vector (Promega, Madison,
WI, USA). The DNA sequences were confirmed by sequencing using an
automated sequencer, i.e., the ABI Prism310 (Applied Biosystems, Foster City,
CA, USA).
Identification of GLIPR1L isoforms
A human testis cDNA library generated from human testis total RNA
(Clontech, Palo Alto, CA, USA) using the Creator SMART cDNA Library
Construction kit (Clontech) was used. To identify and isolate potential isoforms
of GLIPR1L1 and GLIPR1L2, cDNA fragments of GLIPR1L1α (nuclear acids
259–688 of NM_152779) and GLIPR1L2α (nuclear acids 104–613 of
Fig. 8. Analysis of p53 regulation of endogenous hRTVP-1, GLIPR1L1, or
GLIPR1L2 gene expression. (A) QRT-PCR analysis for mRNA levels of
hRTVP-1, GLIPR1L1, and GLIPR1L2 in 293PE cells 24 h following gene
transduction with Ad-p53 or Ad-lacZ. (B) QRT-PCR analysis for mRNA levels
of hRTVP-1, GLIPR1L1, and GLIPR1L2 in a TSU-Pr1 p53 stable clone 24 h
following p53 induction with doxycycline. The effects of p53 expression on
hRTVP-1, GLIPR1L1, and GLIPR1L2 gene expression are expressed as fold of
control. Bars stand for standard errors.
171C. Ren et al. / Genomics 88 (2006) 163–172NM_152436) were used as probes to screen the human testis cDNA library
according to the manufacturer’s protocol (Creator SMART cDNA libraries user
manual; Clontech). Briefly, Escherichia coli cells transformed with the cDNA
library were plated on LB plates at low density. Membrane lifting and
hybridization were performed. Positive colonies were picked and subjected to a
second and third round of screening. Final positive clones were sorted by
restriction mapping. Three clones from each group were sequenced and mapped
using available genomic sequence.
DNA and protein homology search
DNA and protein homology search was performed using programs provided
on the Web site http://www.nlm.nih.gov/BLAST/. Multiple sequence align-
ments were carried out using the BCM search launcher: http://searchlauncher.
bcm.tmc.edu/multi-align/multi-alig.html. Signal peptide and possible cleavage
site prediction was defined using CBS SignalP 3.0: http://www.cbs.dtu.dk/
services/SignalP/. Transmembrane domains were predicted according to PSORT
II Prediction: http://www.psort.ims.u-tokyo.ac.jp/form2.html.
Analysis of gene expression
Human tissues were purchased from BD Biosciences Clontech. Total RNA
from tissues or cell lines was extracted with the RiboPure RNA extraction kit
(Ambion, Austin, TX, USA). The RT reactions were carried out using the High
Capacity cDNA Archive kit (Applied Biosystems) according to the manufac-
turer’s protocol. PCRs were performed using the TaqMan Universal PCRMaster
Mix (Applied Biosystems). The PCR conditions were 80 ng cDNA/well, 50°C
for 2 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for1 min. Duplicate samples were used for PCR. The following TaqMan probe and
primer mixes were used for PCR: Hs00199268_m1(GLIPR1) for hRTVP-1,
Hs00385348_m1 for GLIPR1L1, Hs00380808_m1 for GLIPR1L2, and
4319413E for 18S rRNA (Applied Biosystems). PCRs were performed using
an ABI Prism 7000 Sequence Detection System according to the manufacturer’s
instructions. The fold difference in gene expression of hRTVP-1, GLIPR1L1,
and GLIPR1L2 mRNA was determined by the comparative CT method for
relative quantification. The level of target gene mRNA, normalized by 18S
rRNA or GAPDH, is expressed as 2−ΔΔCT.
p53 binding site analysis
The search ranges for potential p53-bs cover from 2 kb promoter sequence to
intron 4 of hRTVP-1, GLIPR1L1, and GLIPR1L2. The criterion for a p53-bs
candidate is ≥90% identity compared to the p53 cbs: RRRCWWGYYY(n)
RRRCWWGYYY, where R is purine, Y is pyrimidine, W is A or T, and (n) is 0
to 13 of any bases [30]. Each pair of oligonucleotides that were derived from a
putative p53-bs (see Fig. 6 for p53-bs sequences) were annealed and subcloned
into the SmaI site of the pGL3 luciferase reporter vector with a minimal SV40
promoter (Promega). All constructs were confirmed by DNA sequencing. One
microgram of luciferase reporter construct, 0.1 μg of wild-type or mutant
pCMVp53-expressing vectors [41] or control empty vector pcDNA3.1(+), and
0.2 μg pCMV-gal were cotransfected into 148-1PA cells using LipofectAmine
(Invitrogen, Carlsbad, CA, USA). Luciferase activity assay was performed 24 h
after transfection. Luciferase activity was standardized to the cotransfected β-
galactosidase as previously described [24,25] and expressed as fold of control
(control was pcDNA3.1(+) with pGL3 promoter–luciferase vector).
Analysis of p53 regulation of endogenous hRTVP1, GLIPR1L1, or
GLIPR1L2 gene expression
Adenoviral vectors Ad-lacZ and Ad-p53 were generated using standard
recombination protocols. 293PE cells were transduced with Ad-lacZ and Ad-
p53 at an m.o.i. of 50 in serum-free medium for 3 h, at which time complete
medium (high glucose DMEM) was restored. Cell growth continued until
extraction of total RNA at 24 and 48 h following gene transduction.
Human p53 cDNA was inserted into pTRE2hyg to form pTRE2hyg-p53.
pTRE2hyg-p53 was cotransfected together with a Tet-On vector (BD
Biosciences Clontech) into TSU-Pr1 cells using LipofectAmine Plus (Invitro-
gen). The stable clones were selected using 100 μg/ml hygromycin and 500 μg/
ml G418. The induction of p53 expression in these stable clones was analyzed
by QRT-PCR. A representative TSU-PR1 p53 stable clone was used for this
study. p53 expression was induced by incubation of cells with 2 μg/ml
doxycycline in the medium for 24 and 48 h. A parallel control experiment was
conducted by incubation of cells under the same conditions without doxycycline
in the medium. Total RNA from cells was extracted and QRT-PCR was
performed as described above.
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